Nam Insoon of the Democratic Party Calls for “Expanded Support”
“Proper Management Mechanisms Needed for Non-Covered Prices”

As government support for couples struggling with infertility has expanded, the number of patients undergoing infertility treatments or procedures has increased significantly. Along with this rise, the average reported price at medical institutions for key non-insurance (out-of-pocket) infertility items has also seen a sharp increase. Experts point out that, if the expansion of infertility support is to truly alleviate patients' financial burden, there must be simultaneous oversight and management of non-insurance prices.


Nam Insoon, Democratic Party of Korea member. 2026.5.4 Photo by Hyunmin Kim

Nam Insoon, Democratic Party of Korea member. 2026.5.4 Photo by Hyunmin Kim

View original image

According to analysis by Nam Insoon, a Democratic Party of Korea member, of data from the Health Insurance Review & Assessment Service submitted for the National Assembly audit and released on September 21, 2026, the number of infertility patients decreased from 248,397 in 2021 to 242,836 in 2023, then surged by 20.4% to 292,462 in 2024. Likewise, the number of patients undergoing infertility procedures dropped from 143,162 in 2021 to 137,154 in 2023, but then rose by 19.0% to 163,194 in 2024.


Starting in January 2024, the government abolished income criteria for financial support for infertility procedures, making support available regardless of income level. In February of the same year, the number of subsidized in vitro fertilization (IVF) cycles was increased. As a result, medical use related to infertility has also grown in line with this expanded support.


Medical expenses have also climbed. The total cost of infertility treatments rose by 16.9% from 259.6 billion won in 2023 to 303.6 billion won in 2024, while the cost for infertility procedures increased by 35.6% from 272.1 billion won to 368.9 billion won. The average medical expense per patient for infertility procedures also rose by 13.9% during the same period, from 1,983,974 won to 2,260,617 won.


The problem lies in the price of non-insurance items. Between 2021 and 2023, average reported prices of major non-insurance infertility items at medical institutions mostly increased at an annual rate of 1–4%. However, in 2024, price increases greatly accelerated: the cost of sperm retrieval and processing rose by 52.8%, embryo transfer by 28.2%, standard IVF by 14.2%, egg retrieval and processing by 12.9%, and intracytoplasmic sperm injection by 7.4%.


Assemblywoman Nam pointed out the need for price management of non-insurance items in tandem with the expansion of infertility support. She said, "Expanding support for infertility is a necessary policy, but simply increasing subsidies without proper management of non-insurance prices means financial aid may not lead to a real reduction in patient burden and could instead be absorbed by price hikes."



She further emphasized, "Since this program directly supports medical costs using public funds, it is essential to continuously monitor changes in non-insurance prices and establish appropriate management mechanisms alongside the expansion of support."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing